66510-55-2

Usage

Uses

1. Used in Pharmaceutical Research:
1(2H)-Isoquinolinone, 2-(3-chloropropyl)-3,4-dihydro-6,7-dimethoxyis used as a compound of interest for pharmaceutical research due to its potential pharmacological activity and unique chemical structure.
2. Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1(2H)-Isoquinolinone, 2-(3-chloropropyl)-3,4-dihydro-6,7-dimethoxyis used as a starting material or a structural component for the development of new drugs, particularly those targeting the central nervous system or other biological systems.
3. Used in CNS Drug Development:
Given the compound's potential effects on the central nervous system, it is used as a candidate for the development of drugs aimed at treating neurological disorders or conditions.
4. Used in Chemical Synthesis:
1(2H)-Isoquinolinone, 2-(3-chloropropyl)-3,4-dihydro-6,7-dimethoxymay also be used as an intermediate in the synthesis of other complex organic compounds, particularly those with potential applications in the pharmaceutical industry.

Upstream product

• 493-49-2 6,7-dimethoxy-3,4-dihydro-2H-isoquinolin-1-one 
• 109-70-6 1.3-chlorobromopropane 

Downstream Products

• 95092-22-1 6,7-dimethoxy-2-<3-propyl>-1,2,3,4-tetrahydroisochinolinone 

Relevant academic research and scientific papers

Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ2 receptors

σ2 Receptors are promising biomarkers for cancer diagnosis given the relationship between the proliferative status of tumors and their density. With the aim of contributing to the research of σ2 receptor Positron Emission Tomography (PET) probes, we developed 2-[3-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]propyl]-3, 4-dihydroisoquinolin-1(2H)-one (3), with optimal σ2 pharmacological properties and appropriate lipophilicity. Hence, 3 served as the lead compound for the development of a series of dihydroisoquinolinones amenable to radiolabeling. Radiosynthesis for compound 26, which displayed the most appropriate σ2 profile, was developed and σ2 specific binding for the corresponding [18F]-26 was confirmed by in vitro autoradiography on rat brain slices. Despite the excellent in vitro properties, [18F]-26 could not successfully image σ2 receptors in the rat brain in vivo, maybe because of its interaction with P-gp. Nevertheless, [18F]-26 may still be worthy of further investigation for the imaging of σ2 receptors in peripheral tumors devoid of P-gp overexpression.

Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischemic properties

Structural modification of the calcium-antagonist verapamil (1) by replacement of the lipophilic α-isopropylacetonitrile moiety by various heterocyclic ring systems has led to a new class of cardiovascular compounds which are characterized by a specific bradycardic activity. These agents reduce heart rate without binding to classical calcium channels or β-adrenoceptors, interacting instead specifically with structures at the sino atrial node. Therefore they have also been termed sinus node inhibition. The prototype falipamil (2) has been submitted to furthr optimization mainly hy manipulation of the phthalimidine moiety. This has resultd in a secod generation of specific bradycardic agents with increased potency and selectively and prolonged duration of action represented by the benzazepinone-derivative UL-FS 49 (4). Structure-activity relationships within this novel class of compounds have revealed a marked dependence of activity on the substitution pattern of the aromatic rings, the nature of the central nitrogen atom, and the length of the connecting alkyl chains. The crucial role of the benzazepione ring for bradycardic activity can be best explained by its special impact on the overall molecular conformation.

N-(phenylalkylamino-alkyl)-dihydroisoquinolinones, pharmaceutical compositions and methods employing them

Compounds of the formula STR1 wherein R1, R2 and R6, which may be identical to or different from each other, are each hydrogen or lower alkyl; R3 is lower alkoxy; R4 is lower alkoxy or, together with R3, methylenedioxy or ethylenedioxy; R5 is hydrogen, lower alkyl or benzyl; R7 is hydrogen or lower alkoxy; R8 is hydrogen, lower alkoxy or, together with R7, methylenedioxy or ethylenedioxy; M is 1 or 2; and N is 2 or 3; And non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as antihypertensives and heart rate reducers.